Press Releases

Read Regulatory and non-regulatory press releases

  • All
  • Non-Regulatory
  • Regulatory
Regulatory

Notice to Convene an Extraordinary General Meeting

Regulatory

Press Release Oncology Venture Plans Name Change to Allarity Therapeutics and Board Restructuring to Align with Current Company Strategy

Regulatory

Press Release Oncology Venture Publishes Interim Report for the Period January – June 2020

Non-Regulatory

Oncology Venture A/S Invites Investors for Q2 2020 Report Conference Call

Regulatory

Press Release Oncology Venture’s Novel PARP Inhibitor Stenoparib (formerly 2X-121) Shows Anti-Viral Activity Against Coronavirus in Pre-Clinical Studies

Regulatory

Press Release Oncology Venture will offer new shares in exchange for previously annulled warrants as part of clean-up of remaining obligations incurred prior to former management departure

Regulatory

Press Release Oncology Venture calls second investment tranche under its share subscription agreement and issues 5,980,020 shares to Global Corporate Finance

Regulatory

Press Release Oncology Venture issues 1,893,939 shares to Negma Group LTD and Park Partners GP and thereby all outstanding convertible loan notes are converted

Regulatory

Press Release Oncology Venture is issuing 2,255,639 shares under its existing convertible loan note agreement with Negma Group LTD and Park Partners GP

Regulatory

Press release Oncology Venture acquires full ownership of its PARP inhibitor (2X-121) program

Regulatory

Press Release Oncology Venture is issuing 1,574,803 shares under its existing convertible loan note agreement with Negma Group LTD and Park Partners GP

Regulatory

Press release Oncology Venture signs agreement to out-license two pipeline assets as part of prioritized portfolio strategy

Regulatory

Press release Oncology Venture is issuing 5,177,584 shares under its share subscription agreement with Global Corporate Finance

Regulatory

Press Release Oncology Venture terminates agreement with liquidity provider

Regulatory

Press Release Oncology Venture is issuing 2,255,639 shares under its convertible note agreement with Negma Group LTD and Park Partners GB

Regulatory

Press Release Oncology Venture calls first investment tranche of SEK 10 million under its share subscription agreement with Global Corporate Finance

Regulatory

Press Release Oncology Venture is issuing 751,879 shares under its convertible note agreement with Negma Group LTD and Park Partners GB

Regulatory

Press release Oncology Venture acquires full control of Dovitinib program

Regulatory

Company Announcement Oncology Venture Publishes Q1 2020 Report for the Period January – March 2020

Non-Regulatory

Oncology Venture A/S Invites Investors for Q1 2020 Report Conference Call

Want to keep updated on news from Oncology Venture? Sign up to our press releases here: